Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting. Chief Medical Officer & Senior VP Clinical Development, Dr David Stamler had been invited to make an oral presentation at the Parkinson’s ...
![](https://alteritytherapeutics.com/wp-content/uploads/investor-5.jpg)
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme. The refund relates to the cost of eligible research and development activities conducted during the 2019 financial year. These funds will be used to ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). Orphan Drug designation by the EC entitles Alterity to ten years of market exclusivity in the European Union for the ...
Chairman’s Address to Shareholders 2019 AGM
AGM 2019 Presentation
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference. The AGM is scheduled for 9:30 AM (Australian Eastern Daylight Time) Tuesday, November 26th, 2019 at the Adina Apartment Hotel, 189 Queen Street, Melbourne. Registration is from 9:15 AM. To ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on recommending the designation of its lead molecule PBT434 for the treatment of Multiple System Atrophy (MSA) as an orphan medicinal product to the European Commission (EC). Following ...
Highlights: Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in France Presentation at the Janney Healthcare conference in New York Cash balance of $10.7M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the ...
Alterity PBT434 Poster – MDS 2019 Congress
Receive news from Alterity Therapeutics
![](https://alteritytherapeutics.com/wp-content/uploads/hands-cta.png)